Pharmacologic strategies for the prevention of atherosclerotic plaque progression.
Despite improved treatment options, coronary artery disease remains the leading cause of death in men and women in industrialized societies. Reduction of atherosclerotic disease will require the development and evaluation of new classes of pharmacologic agents capable of modifying the development and progression of the atherosclerotic disease process. The direct observation of coronary plaque burden and morphology with in vivo imaging modalities has been evaluated as an end point in serial pharmacologic intervention trials. This review will describe the use of intravascular ultrasound for such studies, summarize results from recent trials and outline potential future pharmacologic targets.